The desire to improve engraftment following transplantation of limited numbers of hematopoietic stem cells (HSC) has spurred the investigation of ex vivo stem cell expansion techniques. While surrogate outcomes, such as an increase in SCID-repopulating cells, suggest successful stem cell expansion in some studies, it is not clear that such assays predict outcomes using a more clinically relevant approach (e.g., myeloablation). We have addressed this by testing three cytokine combinations for their ability to increase the radioprotective and long-term marrow reconstitution capacity of hematopoietic cells cultured ex vivo. Low numbers of light-density (LD) mouse bone marrow (BM) cells or their expanded product were injected into lethally irradiated (9 Gy) congenic recipients. Survival rates and percent donor engraftment were compared at 2, 5, and 7 months post-transplant. 
INTRODUCTION E X VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS
(HSC) would be of value with stem cell grafts known to have low HSC numbers, such as placental cord blood (PCB). With PCB transplants, both the success and speed of neutrophil and platelet engraftment are dependent on the dose of nucleated cells or colony-forming cells (CFC) transplanted per kilogram recipient body weight (1) . This finding underscores the interest in trying to find methods to increase the limited numbers of HSC in such a graft.
Numerous strategies for the expansion of murine and human HSC and progenitor cells have been reported and the studies have included PCB, peripheral blood stem cells (PBSC), and bone marrow (BM) cells (2) (3) (4) (5) (6) (7) (8) (9) (10) . Consistently, the numbers of hematopoietic progenitor cells (CFC of different classes) can be increased in culture with a variety of cytokines in the presence or absence of serum components and/or stromal feeder layers (11) (12) (13) (14) . The use of early-acting cytokines, such as Flt-3 ligand (L), interleukin-11 (IL-11), IL-3, kit-L, IL-6, and thrombopoietin (Tpo), compared to more lineage-restricted cytokines such as granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage (GM)-CSF, and eythropoietin (Epo), would potentially support expansion of HSC numbers rather than their differentiation. However, there is considerable evidence that, regardless of which cytokines are used, ex vivo cell expansion conditions largely facilitate the differentiation of HSC into lineage-restricted progenitor cells (15, 16) .
Several methods have been used to monitor HSC expansion in culture. These methods typically rely on surrogate end points as read-out, such as the number of high proliferative potential (HPP)-CFC, cobblestone area-forming cells (CAFC), and non-obese severe combined immunodeficient mouse (NOD-SCID)-repopulating cells. However, it is not clear whether the output of such ex vivo expansion methods would translate into improved survival and long-term marrow reconstitution in a more challenging setting, such as survival and enhanced donor engraftment following myeloablation and transplantation of a restricted number of cells.
We have addressed this question directly by using a lethally irradiated murine transplant model to assess several cytokine combinations for their ability to increase percent survival and engraftment when limited numbers of BM low-density (LD) cells were expanded ex vivo. Three cytokine combinations were tested: (i) kit-L, Tpo, and Flt-3 L; (ii) cytokines in (i) plus IL-11; (iii) cytokines in (ii) plus IL-3. Mice congenic for the leukocyte marker CD45.1 were either transplanted with limiting numbers of unmanipulated CD45.2 BM LD cells or the expanded product from the original cell dose. Survival rates (radioprotection) and percent donor engraftment in the survivors were compared. The stability of donor engraftment was used to reflect long-term marrow repopulating ability. The results revealed that, with the cytokine combinations used, transplantation of ex vivo-expanded cells either failed to enhance survival or resulted in poorer survival and reduced donor engraftment compared to transplantation of unmanipulated cells.
MATERIALS AND METHODS

Mice
Female C57Bl/6 (Ly-5.2) donors and C57Bl/6 Ly-5.1:Pep3b (Ly-5.1) recipient mice were obtained from Jackson Laboratories (Bar Harbor, ME) and used for transplantation at age 10-14 weeks.
BM and LD cell preparation
BM cells were flushed from femurs and tibias with Iscove's modified Dulbecco's medium (IMDM; Gibco, Gaithersburg, MD) and pooled for further use. LD cells, consisting of the mononuclear cell fraction, were concentrated by centrifugation at 600 3 g for 15 min on Nycoprep (Nycomed, Oslo, Norway; density 1.077). The cells were harvested from the interface, washed, and resuspended in RPMI-1640 medium (Gibco). Nucleated BM and LD cells were counted using a hemocytometer; viability was determined by Trypan Blue dye exclusion.
Recombinant cytokines
The following purified recombinant cytokines were used in different combinations at concentrations previously shown to be optimal for colony growth: 100 ng/ml recombinant (r) rat (r) kit-L; 20 ng/ml r human (h) Epo; 10 ng/ml r murine (m) GM-CSF; 10 ng/ml rh G-CSF (all from Amgen, Thousand Oaks, CA); 100 U/ml rm IL-3 (Pharmingen, San Diego, CA); 100 ng/ml rh Flt-3 L; 20 ng/ml rh IL-11 (both from Genetics Institute, Cambridge, MA); 800 U/ml rmTpo (kindly provided by Dr. Kenneth Kaushansky).
Ex vivo expansion of BM LD cells
LD cells were prepared from freshly harvested BM and cultured in liquid suspension in IMDM which also contained 2% bovine serum albumin (BSA), 10 mM b-mercaptoethanol, 200 mg/ml bovine transferrin (all from Sigma, St. Louis, MO), 10 mg/ml bovine insulin, 100 U and 100 mg/ml penicillin-streptomycin, respectively, 2 mM L-glutamine (all from Gibco), and 2% human lipoprotein concentrate (ICN Pharmaceuticals, Costa Mesa, CA) in 24-well plates for 3 or 5-7 days at 37°C in air supplemented with 5% CO 2 . Cultures were started at 5 3 10 4 LD cells/ml in each well and in the presence of one of the cytokine combinations. Aliquots (10 ml) were withdrawn at different time points for determination of viable cell counts and CFC content. In parallel experiments, cultures were also established in the presence of 5% fetal bovine serum (FBS) to compare the effects of the addition of a complex protein mix to the otherwise serum-deprived culture conditions.
CFC assays
For assessment of GM-CFC, megakaryocyte CFC, and mixed-cell CFC, a standard methylcellulose (MTC) (ACROS, New Jersey, NY) assay was used. Cells withdrawn from the liquid suspension cultures were plated in duplicate in 1-ml Petri dishes containing 15% (vol/vol) horse serum (Gemini Bioproducts, Calabassas, CA), BSA 0.9% (wt/vol), 10 mM b-mercaptoethanol, 100 U and 100 mg/ml penicillin-streptomycin, respectively, 2 mM L-glutamine, and 0.8% MTC (wt/vol) in IMDM. To stimulate colony growth, the same combination of cytokines used for the initiation of the original suspension culture was VON DRYGALSKI ET AL.
added. After 7 days of incubation (37°C, 5% CO 2 ), the colonies were counted using an inverted light microscope.
Transplantation with LD cells
The effect of a range of cell doses on survival was determined by transplantation of 10 4 , 1.5 3 10 4 , 2 3 10 4 , 2.5 3 10 4 , 5 3 10 4 , or 10 5 BM LD cells in groups of 5-7 animals. Control animals received RPMI only or 10 6 unseparated BM cells. Single-dose lethal irradiation (9 Gy from a 137 Cs source at a dose rate of 72 cGy/min) was used in all experiments and transplantation took place within 8 h post-irradiation. For the first 6-8 weeks post-transplant, the mice were maintained in a laminar flow environment in sterilized cages with irradiated food and sterile acidified water supplemented with 2 mg/ml neomycin sulfate (Sigma). Over the course of the study, more than 500 mice were followed for up to 8 months.
Transplantation with ex vivo-expanded BM LD cells
LD cells were transplanted either unmanipulated or as ex vivo-expanded progeny. On day 0, freshly prepared BM LD cells were transplanted at the indicated cell doses and CFC cultures were initiated. To control for handling, all procedures normally performed on expanded cells were also carried out for fresh LD cells on day 0. At the end of the culture period, the total content of each well was harvested and all recovered cells transplanted.
Percent donor engraftment
Percent donor engraftment was determined by twocolor fluorescence-activated cell sorting (FACS) analysis with antibodies (Abs) against the leukocyte markers CD45.1 and CD45.2. Whole blood (10-100 ml) was collected from the tail vein and mixed with 40 ml of a citrate phosphate dextrose adenine solution (Sigma). Cells were incubated with rat anti-mouse CD16/32 monoclonal Ab (Pharmingen) to avoid nonspecific binding to FcgR and then stained using fluorescein isothiocyanate (FITC)-conjugated mouse anti-mouse CD45.2 and phycoerythrin (PE)-conjugated CD45.1 monoclonal Ab (Pharmingen). Control studies were performed with FITC-or PE-conjugated mouse IgG 2a isotype controls (Pharmingen). Two milliliters of FACS lysing solution (Becton Dickinson, San Jose, CA) were added to each sample to lyse red blood cells and the remaining cells were washed twice in phosphate-buffered saline (Gibco, Grand Island, NY). The stained cells were analyzed on a FACScalibur flow cytometer (Becton Dickinson). Ab-labeled leukocytes were identified according to their forward and side-angle light scatter and gated electronically.
For each probe, 1-1.5 3 10 4 events were acquired. Data were processed using CellQuest software (Becton Dickinson).
Statistical analysis
Differences in peripheral blood counts and percent donor engraftment were assessed by Student's t-test. Survival rates were compared by log-rank test.
RESULTS
Ex vivo expansion of BM LD cells
Six cytokine combinations were initially evaluated for progenitor cell expansion. These included: (i) kit-L, Tpo and Flt-3 L; (ii) cytokines in (i) plus IL-11; (iii) cytokines in (ii) plus IL-3; (iv) kit-L, Tpo, and IL-11; (v) kit-L, Tpo, IL-11, and IL-3; (vi) Tpo, GM-CSF, Epo, and IL-3. The first three combinations were finally selected for subsequent experiments because they contained factors thought to affect stem cell homeostasis. With all combinations, cell growth in liquid culture became exponential after 3 days and the peak of cell numbers was seen at 5-7 days. Two to 8 expansion experiments were carried out with each cytokine combination. The average fold-expansion of total cell numbers and numbers of CFC was, respectively, 9-and 11-fold with cytokine combination (i) (n 5 3 experiments), 48-and 46-fold with combination (ii) (n 5 7), 39-and 62-fold with combination (iii) (n 5 7), 36-and 30-fold with combination (iv) (n 5 2), 38-and 56-fold with combination (v) (n 5 8), and 19-and 79-fold with combination (vi) (n 5 2) (Fig. 1) . The CFC recovered after 5-7 days in suspension culture, however, yielded colonies of smaller size than CFC in the initial cell suspension (data not shown).
Transplantation and survival
The ability of different numbers of unmanipulated BM LD cells to rescue lethally irradiated mice was compared. As shown in Fig. 2 , all animals transplanted with 10 6 total BM cells survived (n 5 24). Animals that received no cells died (n 5 36; radiation controls) within the first 4 weeks. Transplantation of lesser numbers of LD cells resulted in decreasing survival rates 10 weeks post-transplant. Because of insignificant differences in the results obtained between relatively small ranges of cell dose, certain cell doses were combined for analysis. Thus, survival was 20-30% (n 5 77), 40-70% (n 5 66), and 90-100% (n 5 40) with 1-1.5 3 10 4 , 2-2.5 3 10 4 , and 0.5-10 5 LD cells, respectively. The differences in survival rates were statistically highly significant (p values for the different comparisons ranging between 0.0001 and 0.01). After the first 10 weeks, death rates slowed with only modest changes in percent survival thereafter (Fig.  2) . With this as background, we reasoned that as little as a two-fold increase in HSC numbers by means of expansion should result in detectably better post-transplant survival rates.
We then tested the ability of ex vivo-expanded cells to rescue lethally irradiated recipients. After cells were ex- 
With cytokine combination (iii), different groups were transplanted with either 10 4 or 2.5 3 10 4 fresh LD cells or their cell products expanded for 3 or 7 days.
At 7 months, the survival rate of mice transplanted with 2 3 10 4 LD cells was 50%, whereas the survival rates of mice transplanted with cells expanded in culture for 3 or 5 days with cytokine combination (i) were 20% (p 5 0.34) and 14% (p 5 0.05), respectively (Fig. 3) . Fig. 4) .
Survival rates after transplantation with cells expanded with cytokine combination (iii) from 10 4 LD cells for 3 or 7 days were 6% and 22%, respectively, as compared to 17% survival with unmanipulated cells (p 5 0.4-0.5) (Fig. 5) . Survival rates were 30% and 20%, respectively, when the progeny of 2.5 3 10 4 cells were transplanted, whereas the survival rate with unmanipulated cells was 60% (p 5 0.07 for unmanipulated cells versus cells cultured for 3 days and p 5 0.004 for unmanipulated cells versus cells cultured for 7 days) (Fig. 6) . No significant differences in survival were observed based on the different cytokine combinations used or whether the liquid suspension cultures were established in the presence of 5% FBS (data not shown).
Percent donor engraftment
As shown in Fig. 7 , when 10 4 LD cells were transplanted, the mean percent donor engraftment at 10 weeks, 5 months, and 7 months was 43 (SEM 35%), 54 (SEM 33%), and 55 (SEM 36%), respectively. At these same time points, the mean percent donor engraftment was 49 (SEM 29%), 55 (SEM 36%), and 56 (36%), respectively, when 2-2.5 3 10 4 LD cells were transplanted. There was no significant difference in engraftment between the groups of mice that received 10 4 or 2-2.5 3 10 4 LD cells (p . 0.05). Mean percent donor engraftment in mice that received 5 3 10 4 LD cells or 10 6 unseparated BM cells was 74 (SEM 16%) and 90 (SEM 3%) at 10 weeks, 68 (SEM 25%) and 95 (SEM 1%) at 5 months, and 76% (SEM 21%) and 93% (SEM 3%) at 7 months (all p values ,0.05). The differences in engraftment rates between mice that were injected with 10 4 LD cells and 5 3 10 4 LD cells or 2-2.5 3 10 4 LD cells and 5 3 10 4 LD cells were significant at week 10, only (p , 0.05).
Five and 7 months post-transplant, some of the mice with low engraftment levels in the groups injected with 10 4 or 2-2.5 3 10 4 LD cells had died, so that differences became less prominent (p . 0.05; Fig. 7 ). In general, the transplantation of low numbers of cells (i.e., 10 4 or 2-2. the Ly marker system. In most cases, there was a decrement in donor engraftment in those mice that had received expanded cells, although the decrement only occasionally reached statistical significance. In no case did ex vivo expansion improve engraftment parameters (data not shown).
DISCUSSION
A correlation between nucleated cell dose and the success and speed of both neutrophil and platelet engraftment following transplantation of PCB is well established (17) . In addition, CFC dose, measured as the total num- ber of GM-CFC, erythroid burst-forming cells (BFU-E), and mixed-cell CFC transplanted per kilogram of recipient body weight, correlates even more strongly with engraftment kinetics (1) . The goal of improving the rate of engraftment as well as reducing the time to recovery of marrow function has spurred investigation of methods to increase the number of HSC and progenitor cells, not only with PCB but also with other stem cell sources.
Consistently, the numbers of hematopoietic progenitor cells (CFC of different classes) and of cells with "stem cell-like" characteristics can be increased in culture with a variety of cytokines in the presence or absence of serum components and/or stromal feeder layers (2-16). In vitro characteristics of candidate HSC, such as long-term culture-initiating cells (LTC-IC), CAFC, and HPP-CFC, or expression of primitive cell-surface markers such as CD34, AC133, and c-kit, may serve as surrogate stem cell markers. However, in vitro growth characteristics and phenotypically identified candidate HSC might not always translate into HSC function in vivo-especially once HSC have been subjected to ex vivo expansion.
Reliable assessment of HSC function following transplantation, therefore, necessitates animal studies. The two most frequently used models are the NOD-SCID mouse and competitive repopulation studies employing cells that can be distinguished by markers such as the CD45.1 and CD45.2 congenic leukocyte markers.
To date, the results of the vast majority of studies, either in vitro or in vivo, do not provide conclusive evidence that HSC function can be increased (18) (19) (20) (21) (22) (23) (24) (25) . With the NOD-SCID mouse and competitive repopulation models, donor chimerism can be evaluated in each animal, but the capacity of expanded HSC to rescue irradiated animals (radioprotection) cannot be critically assessed.
In the experiments reported here, we have transplanted varying and limiting numbers of BM LD cells (that would, of necessity, contain varying and limiting numbers of HSC), and compared the outcomes to transplantation of their progeny expanded with different cytokine combinations for different periods of time up to 1 week. We found that transplantation of cell doses of 10 4 , 2-2.5 3 10 4 , and 0.5-1.0 3 10 5 LD cells into lethally irradiated mice resulted in 20-30%, 40-70%, and 90-100% survival, respectively. Therefore, we reasoned that as little as a two-fold increase in HSC by means of ex vivo expansion should result in detectably better survival rates, especially at the lower cell doses.
The cytokine combinations chosen for HSC expansion were selected because they had been well studied and included those thought to act on early stem and progenitor cells: kit-L, Tpo, and Flt-3 L (10, 11, 14, 15, 24, (26) (27) (28) (29) (30) . The three different combinations gave different degrees of CFC expansion. The addition of IL-11 to cytokine combination (i) and then IL-3 to cytokine combination (ii) would provide evidence if single cytokines influenced survival rates and engraftment levels in the transplanted animals. Previous reports indicated that the addition of IL-3 to cell cultures prior to transplantation had a detrimental effect on long-term engraftment in the sheep (31) as well as in the NOD-SCID mouse (21, 32) . Although our results with cytokine combinations containing IL-3 were not positive, the results obtained by transplanting cells exposed to IL-3 were not demonstrably worse.
In our model, none of the cytokine combinations used for cell expansion significantly enhanced short-term or long-term survival or percent donor engraftment following transplantation. These findings are consistent with a number of earlier studies (24, (33) (34) (35) However, when cells were cultured for 9 days, all SRC were lost (22) . Similar results were reported by Mobest et al., who cultured CD34 1 cells from cytokine-mobilized PB with Flt-3 L, kit-L, and IL-3. Cells cultured past day 4 lost their engraftment potential in NOD/SCID mice even though an increase in the numbers of LTC-IC was seen (23) . In transplant studies employing larger animals, no benefit of ex vivo expansion has been shown (39) (40) (41) .
One reason for a lack of ability to expand HSC numbers ex vivo is that only recently have the molecular mechanisms underlying the process of HSC self-renewal begun to emerge. Reya showed that soluble Wnt3a protein was able to expand murine HSC as determined both by phenotypic analysis as well as in a competitive repopulation assay (42, 43) . These studies were performed with purified murine HSC, and it remains to be determined if the same effects will be evident when whole BM is employed. In related experiments, Lessard et al. and Park et al. have demonstrated an important role for the proto-oncogene BMi-1 in both normal and leukemic stem cell homeostasis (45, 46) . How the Wnt signaling pathway and Bmi-1 intersect remains to be determined.
To assess the effect of ex vivo expansion on the radioprotective capacity and the long-term marrow reconstitution ability of HSC, we have employed an animal model that critically tests success of engraftment (survival) and reconstitution (percent donor engraftment) by transplanting limited numbers of either unmanipulated or ex vivo-expanded murine LD BM cells. This model gives highly reproducible survival curves, allowing the testing and comparison of expansion strategies. Different cytokine combinations and culture conditions were tested in the ex vivo expansion phase, and the results clearly demonstrated a detrimental effect of ex vivo expansion on HSC function. None of the cytokine combinations or conditions used for expansion enhanced survival or percent donor engraftment in the recipients. It will be of great interest to determine if proteins of the Wnt family will be effective in transplantation models that require the expansion of limited numbers of stem cells for survival and successful long-term engraftment.
